Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today
Key Points
A Wells Fargo analyst cut his price target on Ultragenyx stock, though it still implies significant upside from yesterday's closing price.
Ultragenyx reported yesterday that two Phase 3 studies failed to achieve primary endpoints for setrusumab.
Despite the Wells Fargo analyst's positive outlook, Ultragenyx stock should only remain a consideration for those comfortable with more speculative investments.
- 10 stocks we like better than Ultragenyx Pharmaceutical ›
While Ultragenyx Pharmaceutical (NASDAQ: RARE) provided the market with disappointing news yesterday -- shares plunged more than 42% -- it appears that investors aren't completely writing off the company's potential as a developer of treatments for rare diseases. A firm's favorable view of Ultragenyx stock is motivating some investors to click the buy button today, helping the stock recover from its recent decline.
As of 2:51 p.m. ET, shares of Ultragenyx are up 13.2%.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
Despite the company's setback, one analyst maintains an auspicious outlook
Maintaining an overweight rating, Wells Fargo analyst Benjamin Burnett reduced the price target on Ultragenyx stock to $45 from $65 today.
According to TheFly.com, Burnett informed investors in a research note that the stock now features a favorable risk-reward profile, anticipating feedback from the Food and Drug Administration (FDA) regarding setrusumab, as it provided statistically significant results with respect to bone mineral density in its Phase 3 studies. Moreover, Burnett stated that "it's too soon to throw in the towel" on Ultragenyx.
With Ultragenyx stock closing at $19.72 yesterday, Burnett's $45 price target implies upside of more than 128%.
Ultragenyx reported yesterday that its Phase 3 Oribt and Cosmic studies of setrusumab for osteogenesis imperfecta failed to achieve their primary endpoints; however, they did achieve secondary endpoints, including improvements in bone mineral density.
Should investors add Ultragenyx stock to their buy list?
While Burnett's positive sentiment on Ultragenyx stock is worth acknowledgment, it's far from a cause, in and of itself, to make the pharmaceutical stock a buy. Ultragenyx generates revenue from the sales of several products, but it consistently incurs net losses. At this point, therefore, Unltragenyx stock should only remain a consideration for those with higher risk tolerances.
Should you buy stock in Ultragenyx Pharmaceutical right now?
Before you buy stock in Ultragenyx Pharmaceutical, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ultragenyx Pharmaceutical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $507,744!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,153,827!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of December 30, 2025.
Wells Fargo is an advertising partner of Motley Fool Money. Scott Levine has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
